The Acton, Massachusetts–based maker of Omnipod insulin delivery systems posted profits of $29.2 million, or 42¢ per share, on sales of $307.7 million for the three months ended Dec. 31, 2021, for a massive bottom-line gain from losses of $17.1 million the year prior on sales growth of 25%.
Get the full story at our sister site, Drug Delivery Business News.